Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver-limited Metastasis
NCT06848465Phase 1Recruiting
- Start
- Feb 2025
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tislelizumab in colorectal cancer (CRC) and liver metastasis. Primary endpoint: Incidence of treatment-emergent adverse events at 3 years. Started Feb 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
colorectal cancer (CRC)liver metastasis
Beyond the preview
Go deeper on NCT06848465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06848465.